Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Ian C. Scott, Samantha Hider, David L. Scott
Drug Safety (2018) Vol. 41, Iss. 7, pp. 645-653
Closed Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

Atopic dermatitis
Sinéad Langan, Alan D. Irvine, Stephan Weidinger
The Lancet (2020) Vol. 396, Iss. 10247, pp. 345-360
Closed Access | Times Cited: 1288
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
Dennis McGonagle, James S. O’Donnell, Κassem Sharif, et al.
The Lancet Rheumatology (2020) Vol. 2, Iss. 7, pp. e437-e445
Open Access | Times Cited: 800
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas, Cristián Hernández-Rocha, Marjolijn Duijvestein, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 6, pp. 323-337
Closed Access | Times Cited: 476
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
Roy Fleischmann, Aileen L. Pangan, In‐Ho Song, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 11, pp. 1788-1800
Closed Access | Times Cited: 357
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Farzan Solimani, Katharina Meier, Kamran Ghoreschi
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 247
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Anniina Virtanen, T. Haikarainen, Juuli Raivola, et al.
BioDrugs (2019) Vol. 33, Iss. 1, pp. 15-32
Open Access | Times Cited: 245
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler, et al.
The Lancet (2018) Vol. 392, Iss. 10162, pp. 2378-2387
Open Access | Times Cited: 235
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 760-770
Open Access | Times Cited: 228
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
Justin Stebbing, Ginés Sánchez Nievas, Marco Falcone, et al.
Science Advances (2020) Vol. 7, Iss. 1
Open Access | Times Cited: 201
JAK Inhibitors for Atopic Dermatitis: An Update
Helen He, Emma Guttman‐Yassky
American Journal of Clinical Dermatology (2018) Vol. 20, Iss. 2, pp. 181-192
Closed Access | Times Cited: 193
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley Cohen, Ronald van Vollenhoven, Kevin Winthrop, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 3, pp. 304-311
Open Access | Times Cited: 189
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
Maël Heiblig, Marcela A. Ferrada, Matthew T. Koster, et al.
Blood (2022) Vol. 140, Iss. 8, pp. 927-931
Open Access | Times Cited: 153
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
RMD Open (2020) Vol. 6, Iss. 3, pp. e001395-e001395
Open Access | Times Cited: 144
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
Léa Hoisnard, Bénédicte Lebrun‐Vignes, Sébastien Maury, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 100
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 182-188
Closed Access | Times Cited: 90
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
Roy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002012-e002012
Open Access | Times Cited: 83
JAK inhibitors for rheumatoid arthritis
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 4, pp. 333-344
Closed Access | Times Cited: 43
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Miguel Nogueira, L. Puig, Tiago Torres
Drugs (2020) Vol. 80, Iss. 4, pp. 341-352
Closed Access | Times Cited: 137
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
Thomas Bieber, Jacob P. Thyssen, Kristian Reich, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 2, pp. 476-485
Open Access | Times Cited: 125
Venous Thromboembolism Risk With JAK Inhibitors: A Meta‐Analysis
Mark Yates, Amanda Mootoo, Maryam Adas, et al.
Arthritis & Rheumatology (2020) Vol. 73, Iss. 5, pp. 779-788
Open Access | Times Cited: 123
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 10, pp. 1305-1319
Open Access | Times Cited: 113
Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Kata P. Szilveszter, Tamás Németh, Attila Mócsai
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 109
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 10, pp. 1320-1332
Open Access | Times Cited: 98
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
William Damsky, Danielle Peterson, Julie Y. Ramseier, et al.
Journal of Allergy and Clinical Immunology (2020) Vol. 147, Iss. 3, pp. 814-826
Closed Access | Times Cited: 90
Current and future status of JAK inhibitors
Donal P. McLornan, Janet Pope, Jason Gotlib, et al.
The Lancet (2021) Vol. 398, Iss. 10302, pp. 803-816
Closed Access | Times Cited: 89
Page 1 - Next Page

Scroll to top